Park Avenue Securities LLC Lowers Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Park Avenue Securities LLC decreased its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZGet Rating) by 24.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,030 shares of the specialty pharmaceutical company’s stock after selling 993 shares during the quarter. Park Avenue Securities LLC’s holdings in Jazz Pharmaceuticals were worth $404,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Jazz Pharmaceuticals by 1.0% in the first quarter. Vanguard Group Inc. now owns 5,602,650 shares of the specialty pharmaceutical company’s stock valued at $872,164,000 after acquiring an additional 57,949 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Jazz Pharmaceuticals by 2.7% in the second quarter. JPMorgan Chase & Co. now owns 3,377,061 shares of the specialty pharmaceutical company’s stock valued at $526,855,000 after acquiring an additional 87,895 shares in the last quarter. Wellington Management Group LLP raised its holdings in Jazz Pharmaceuticals by 7.5% in the first quarter. Wellington Management Group LLP now owns 2,625,134 shares of the specialty pharmaceutical company’s stock valued at $408,654,000 after acquiring an additional 184,124 shares in the last quarter. State Street Corp raised its holdings in Jazz Pharmaceuticals by 0.6% in the first quarter. State Street Corp now owns 2,345,235 shares of the specialty pharmaceutical company’s stock valued at $365,083,000 after acquiring an additional 14,293 shares in the last quarter. Finally, Samlyn Capital LLC raised its holdings in Jazz Pharmaceuticals by 28.1% in the second quarter. Samlyn Capital LLC now owns 1,203,559 shares of the specialty pharmaceutical company’s stock valued at $187,767,000 after acquiring an additional 264,146 shares in the last quarter. Hedge funds and other institutional investors own 89.79% of the company’s stock.

Jazz Pharmaceuticals Trading Up 0.7 %

Shares of JAZZ stock opened at $157.24 on Friday. The firm has a 50-day moving average price of $154.48 and a 200 day moving average price of $150.06. Jazz Pharmaceuticals plc has a twelve month low of $125.36 and a twelve month high of $169.98. The company has a market capitalization of $9.90 billion, a price-to-earnings ratio of -524.13, a PEG ratio of 0.89 and a beta of 0.74. The company has a current ratio of 3.16, a quick ratio of 2.27 and a debt-to-equity ratio of 2.07.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Rating) last announced its earnings results on Wednesday, November 9th. The specialty pharmaceutical company reported $4.53 earnings per share for the quarter, beating the consensus estimate of $4.35 by $0.18. Jazz Pharmaceuticals had a negative net margin of 0.52% and a positive return on equity of 30.71%. The firm had revenue of $940.65 million during the quarter, compared to the consensus estimate of $939.88 million. Research analysts forecast that Jazz Pharmaceuticals plc will post 15.24 earnings per share for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In related news, SVP Finbar Larkin sold 197 shares of the business’s stock in a transaction dated Monday, November 14th. The shares were sold at an average price of $149.33, for a total value of $29,418.01. Following the completion of the transaction, the senior vice president now owns 19,409 shares of the company’s stock, valued at approximately $2,898,345.97. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, SVP Finbar Larkin sold 197 shares of the company’s stock in a transaction dated Monday, November 14th. The shares were sold at an average price of $149.33, for a total transaction of $29,418.01. Following the completion of the transaction, the senior vice president now owns 19,409 shares of the company’s stock, valued at approximately $2,898,345.97. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 2,000 shares of the company’s stock in a transaction dated Thursday, November 10th. The shares were sold at an average price of $150.00, for a total transaction of $300,000.00. Following the transaction, the chief executive officer now directly owns 372,028 shares of the company’s stock, valued at approximately $55,804,200. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,258 shares of company stock valued at $2,817,148. 4.40% of the stock is owned by insiders.

Analysts Set New Price Targets

JAZZ has been the topic of a number of research analyst reports. Needham & Company LLC cut their price objective on shares of Jazz Pharmaceuticals from $210.00 to $208.00 and set a “buy” rating on the stock in a report on Thursday, November 10th. Royal Bank of Canada lifted their target price on shares of Jazz Pharmaceuticals from $206.00 to $207.00 and gave the company an “outperform” rating in a report on Thursday, November 10th. The Goldman Sachs Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and lowered their price objective for the company from $192.00 to $190.00 in a research report on Thursday, December 8th. Finally, StockNews.com upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Monday, November 21st. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $202.55.

About Jazz Pharmaceuticals

(Get Rating)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.

Recommended Stories

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc (NASDAQ:JAZZGet Rating).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.